Risk of cancer in rheumatoid arthritis patients taking biologic therapy (tumor necrosis factor antagonists)

MS Patient’s ‘Pick of the Week’ News 
July 14, 2016
World Hepatitis Day Sheds Light on Hepatitis C, Smoking, and Liver Cancer’s Connection 
July 15, 2016
Show all

Risk of cancer in rheumatoid arthritis patients taking biologic therapy (tumor necrosis factor antagonists)

Rheumatoid arthritis patients taking biologic therapy medications have a higher risk of certain cancers.

Rheumatoid arthritis (RA) patients taking biologic therapy (tumor necrosis factor antagonists) have a higher risk of certain cancers, according to research. The risk of cancer in RA patients on biologics has long been a controversial topic, so researchers decided to compare relative risk of cancer in RA patients taking biologics and patients taking non-biologic disease-modifying antirheumatic drugs (nbDMARDs).

For the study, researchers conducted a nationwide cohort study between 1997 and 2011 using the Taiwan National Health Insurance Research Database. Relative risk of cancer was compared between patients taking either biologics or nbDMARDs.

The researchers compared 4,426 new users of the biologic therapy and 17,704 nbDMARD users. Incidence risk of cancer was 5.35 and 7.41 per 1,000 person-years, respectively.

The study concluded that overall there was a lower risk of cancer in patients on biologics, except for hematologic cancer, compared to those taking nbDMARDs.

Read Full Article: Risk of cancer in rheumatoid arthritis patients taking biologic therapy (tumor necrosis factor antagonists): Study

Read Full Article: Risk of cancer in rheumatoid arthritis patients taking biologic therapy (tumor necrosis factor antagonists): Study

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.